Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing

References

• Harrison P. Platelet function analysis. Blood Rev 2005; 19: 111–123
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e489–493
   PubMed Web of Science ®Google Scholar
• Bednar B, Condra C, Gould RJ, Connolly TM. Platelet aggregation monitored in a 96 well microplate reader is useful for evaluation of platelet agonists and antagonists. Thromb Res 1995; 77: 453–463
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Dhanji AR, Truss NJ, Zain ZN, Tucker AT, Mitchell JA, Warner TD. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost 2009; 102: 772–778
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Truss NJ, Ali FY, Dhanji AA, Vojnovic I, Zain ZN, Bishop-Bailey D, Paul-Clark MJ, Tucker AT, Mitchell JA, et al. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 2008; 6: 1933–1943
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y(12) receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost: JTH 2011; 9: 552–561
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: A report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029
   PubMed Web of Science ®Google Scholar
• Jennings I, Woods TA, Kitchen S, Walker ID. Platelet function testing: Practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008; 61: 950–954
   PubMed Web of Science ®Google Scholar
• Sun B, Tandon NN, Yamamoto N, Yoshitake M, Kambayashi J. Luminometric assay of platelet activation in 96-well microplate. Biotechniques 2001; 31: 1174, 1176, 1178 passim
   PubMedGoogle Scholar
• Truss NJ, Armstrong PC, Liverani E, Vojnovic I, Warner TD. Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. J Thromb Haemost 2009; 7: 1897–1905
   PubMed Web of Science ®Google Scholar
• The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. Guidelines on platelet function testing. J Clin Pathol 1988; 41: 1322–1330
   PubMedGoogle Scholar
• Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, Santonastaso C. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994; 216: 444–450
   PubMed Web of Science ®Google Scholar
• Krause S, Scholz T, Temmler U, Losche W. Monitoring the effects of platelet glycoprotein IIb/IIIa antagonists with a microtiter plate method for detection of platelet aggregation. Platelets 2001; 12: 423–430
   PubMed Web of Science ®Google Scholar
• Moran N, Kiernan A, Dunne E, Edwards RJ, Shields DC, Kenny D. Monitoring modulators of platelet aggregation in a microtiter plate assay. Anal Biochem 2006; 357: 77–84
   PubMed Web of Science ®Google Scholar
• Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009; 29: 706–711
   PubMed Web of Science ®Google Scholar
• Ali FY, Hall MG, Desvergne B, Warner TD, Mitchell JA. PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha–brief report. Arterioscler Thromb Vasc Biol 2009; 29: 1871–1873
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 2009; 8: 613–615
   PubMedGoogle Scholar
• Truss NJ, Beavis J, MacCallum PK, Harrison P, Warner TD. Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96-well microtiter plates. J Thromb Haemost 2009; 7: 1226–1228
   Google Scholar
• Moffat KA, Plumhoff E, Reyes E, Hoffman S, Israels S, Meijer P, Hayward CP. The interpretation of light transmittance platelet aggregation is inconsistent – results from an international challenge. J Thromb Haemost 2009; 7: 159
   Google Scholar
• Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: Autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007; 92: 694–697
   PubMed Web of Science ®Google Scholar
• Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527–533
   PubMed Web of Science ®Google Scholar
• Peace AJ, Tedesco AF, Foley DP, Dicker P, Berndt MC, Kenny D. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. J Thromb Haemost 2008; 6: 2027–2034
   PubMed Web of Science ®Google Scholar
• Saw J, Madsen EH, Chan S, Maurer-Spurej E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008; 52: 1826–1833
   PubMed Web of Science ®Google Scholar
• di Minno G, Bertele V, Bianchi L, Barbieri B, Cerletti C, Dejana E, de Gaetano G, Silver MJ. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. Thromb Haemost 1981; 45: 103–106
   PubMedGoogle Scholar
• Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781–788
   PubMed Web of Science ®Google Scholar
• Riess H, Hofling B, von Arnim T, Hiller E. Thromboxane receptor blockade versus cyclooxigenase inhibition: Antiplatelet effects in patients. Thromb Res 1986; 42: 235–245
   Google Scholar
• Silver MJ, Smith JB, Ingerman C, Kocsis JJ. Arachidonic acid-induced human platelet aggregation and prostaglandin formation. Prostaglandins 1973; 4: 863–875
   PubMed Web of Science ®Google Scholar
• Ts'ao C, Holly CM. Arachidonic acid causes lysis of human platelets in an artificial medium: Protection by plasma. Prostaglandins 1979; 17: 775–784
   Google Scholar
• Cho MJ, Liu J, Pestina TI, Steward SA, Thomas DW, Coffman TM, Wang D, Jackson CW, Gartner TK. The roles of alpha IIb beta 3-mediated outside-in signal transduction, thromboxane A2, and adenosine diphosphate in collagen-induced platelet aggregation. Blood 2003; 101: 2646–2651
   PubMed Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Low-dose aspirin is a selective inhibitor of platelet cyclooxygenase activity in healthy subjects. Adv Prostaglandin Thromboxane Leukot Res 1983; 11: 259–264
   Google Scholar
• Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, Tack-Goldman K, Gay WA, Jr. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308: 800–805
   PubMed Web of Science ®Google Scholar
• Cattaneo M. ADP receptors: Inhibitory strategies for antiplatelet therapy. Drug News Perspect 2006; 19: 253–259
   PubMedGoogle Scholar
• Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 2005; 108: 180–192
   PubMedGoogle Scholar
• Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006; 46: 277–300
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357–374
   PubMed Web of Science ®Google Scholar
• Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, Cook RJ, Heddle NM. Diagnostic utility of light transmission platelet aggregometry: Results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7: 676–684
   PubMed Web of Science ®Google Scholar